Cardiovascular Drugs Market by Drug Type (Angiotensin Inhibitors, Anticoagulants, Antihyperlipidemic), Disease Indication (Arrhythmia, Coronary Artery Disease, Hyperlipidaemia), Route of Administration, Mode of Purchase, End-Users - Global Forecast 2024-2

Cardiovascular Drugs Market by Drug Type (Angiotensin Inhibitors, Anticoagulants, Antihyperlipidemic), Disease Indication (Arrhythmia, Coronary Artery Disease, Hyperlipidaemia), Route of Administration, Mode of Purchase, End-Users - Global Forecast 2024-2030

The Cardiovascular Drugs Market size was estimated at USD 82.65 billion in 2023 and expected to reach USD 90.13 billion in 2024, at a CAGR 9.15% to reach USD 152.61 billion by 2030.

Cardiovascular drugs encompass the range of medications prescribed for the treatment of heart diseases and related circulatory problems. This includes a variety of therapeutic drug classes, such as antihypertensives, anticoagulants, antiarrhythmics, antianginals, and cholesterol-lowering drugs. These medications are primarily used in the clinical management of conditions such as hypertension, hyperlipidemia, coronary artery disease, arrhythmias, and heart failure. The increasing incidence of cardiovascular conditions globally, especially among the aging population, is expanding the need for cardiovascular drugs. Rising healthcare spending and improvements in healthcare infrastructure in emerging economies are propelling market expansion. Adverse drug reactions and safety concerns lead to product recalls and tarnish the brand image, subsequently impacting the market growth. New advances in personalized medicine and biologics are presenting significant opportunities in the cardiovascular drug market. Additionally, rising research & development activities to introduce novel cardiovascular are expected to fuel the market growth.

Regional Insights

The Americas maintain a significant position in the global cardiovascular drugs market because of high healthcare expenditure, sophisticated healthcare infrastructure, and significant research and development activities. The U.S. market exhibits strong demand for innovative and branded drugs bolstered by a consumer base that prioritizes efficacy and brand reputation. The European Union (EU) countries exhibit a strong demand for cardiovascular drugs with a large aging population. Market dynamics in the EU are shaped by rigorous regulations and the presence of numerous global pharmaceutical players. There is a mix of preference for brand-name drugs and generics driven by cost-containment measures within various healthcare systems. In the Middle East and Africa, the market for cardiovascular drugs is evolving with rising incidence rates of heart diseases. The Asia Pacific region is rapidly emerging as a significant market for cardiovascular drugs, driven by a growing aging population and an increasing prevalence of cardiovascular diseases (CVDs). In this region, China and India are significant countries due to their large populations and the burgeoning incidence of CVDs. In terms of consumer needs, access to affordable healthcare and generic medicine is paramount due to diverse economic strata across the region.

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the Cardiovascular Drugs Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising Prevalence of Cardiovascular Disorders
    • Increasing R&D Investments for Drug Development
    • Government Initiatives for Prevention & Control of Cardiovascular Diseases
    • Market Restraints
      • Product Recalls and High Cost of Cardiovascular Drugs
      • Market Opportunities
        • Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
        • Introduction of Novel Drugs for Treatment of Cardiovascular Diseases
        • Market Challenges
          • Complexities in Efficient and Safe Drug Development
          • Market Segmentation Analysis
            • Drug Type: Increasing need for angiotensin inhibitors to treat certain types of kidney diseases
            • Disease Indication: Rising usage of cardiovascular diseases for the management of hypertension
            • Mode of Purchase: Rising usage of over-the-counter cardiovascular drugs for managing minor symptoms associated with heart health
            • End-Users: Growing adoption of cardiovascular drugs by hospitals pharmacies for the treatment of acute conditions
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cardiovascular Drugs Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cardiovascular Drugs Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • Bristol Myers pours USD 100 million into RNA drugs for cardiovascular diseases
              
              Bristol Myers Squibb has invested over USD 100 million to enhance its collaboration with Avidity Biosciences. This strategic move underscores Bristol Myers' confidence in Avidity's innovative RNA-based therapy platform. This bold expansion marks a significant milestone in Bristol Myers Squibb’s quest to revolutionize the future landscape of cardiovascular medicine.
              
              U.S. FDA Approves Lexicon Pharma's Drug for Heart Failure
              
              In a significant development for Lexicon Pharmaceuticals Inc., the U.S. Food and Drug Administration (FDA) has officially approved the company's novel oral medication, sotagliflozin, to be marketed as Inpefa for the expansive treatment of heart failure, including for those patients living with type 2 diabetes. This approval marks a milestone for Lexicon, as sotagliflozin represents the first drug by Lexicon to receive endorsement from the FDA, an achievement accentuated by the drug's prior unsuccessful attempt to secure approval as a supplementary treatment to insulin for type 1 diabetes.
              
              Glenmark Pharmaceuticals Launches Drug to Treat Heart Failure in India
              
              Glenmark Pharmaceuticals has announced the Indian market launch of its novel combination therapy, 'Sacu V', a tablet containing sacubitril and valsartan, expressly indicated for heart failure treatment. Upholding a cost-effective strategy, 'Sacu V' is offered at a competitive price, with the 50mg dosage variant (comprising 24mg of sacubitril and 26mg of valsartan) available at INR 19 per tablet.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cardiovascular Drugs Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the Cardiovascular Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Apotex Inc., AstraZeneca PLC, Auro Pharma Inc., Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Chiesi USA, Inc., Cipla Limited, Cornerstone Therapeutics Inc., CYTOKINETICS, Incorporated, Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Ferring B.V., Gilead Sciences, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co., Ltd., Par Pharmaceutical by Endo International, Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., WellSpring Pharmaceutical Corporation, and Zydus Group.
            
            Market Segmentation & Coverage
            
            This research report categorizes the Cardiovascular Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Drug Type
              • Angiotensin Inhibitors
              • Anticoagulants
              • Antihyperlipidemic
              • Antihypertensive
              • Antiplatelet Drugs
              • Disease Indication
                • Arrhythmia
                • Coronary Artery Disease
                • Hyperlipidaemia
                • Hypertension
                • Route of Administration
                  • Intravenous
                  • Oral
                  • Subcutaneous
                  • Mode of Purchase
                    • Over-The-Counter Drugs
                    • Prescription-Based Drugs
                    • End-Users
                      • Hospital Pharmacies
                      • Online Pharmacies
                      • Retail Pharmacies
                      • Region
                        • Americas
                          • Argentina
                          • Brazil
                          • Canada
                          • Mexico
                          • United States
                            • California
                            • Florida
                            • Illinois
                            • New York
                            • Ohio
                            • Pennsylvania
                            • Texas
                            • Asia-Pacific
                              • Australia
                              • China
                              • India
                              • Indonesia
                              • Japan
                              • Malaysia
                              • Philippines
                              • Singapore
                              • South Korea
                              • Taiwan
                              • Thailand
                              • Vietnam
                              • Europe, Middle East & Africa
                                • Denmark
                                • Egypt
                                • Finland
                                • France
                                • Germany
                                • Israel
                                • Italy
                                • Netherlands
                                • Nigeria
                                • Norway
                                • Poland
                                • Qatar
                                • Russia
                                • Saudi Arabia
                                • South Africa
                                • Spain
                                • Sweden
                                • Switzerland
                                • Turkey
                                • United Arab Emirates
                                • United Kingdom
                                
                                
                                Please Note: PDF & Excel + Online Access - 1 Year